The company depends on a limited number of third-party suppliers for raw materials used in manufacturing its diagnostic products and product candidates. It does not have supply agreements in place, which presents risks related to pricing, availability, quality, and delivery schedules. Interruptions or performance issues with these suppliers could significantly impact production and delay development, commercialization, clinical trials, and regulatory approvals. The company may encounter difficulties in securing alternative suppliers on reasonable terms and timelines, potentially affecting its business operations.
Co Diagnostics Inc's Comment on Supply Chain
The company depends on a limited number of third-party suppliers for raw materials used in manufacturing its diagnostic products and product candidates. It does not have supply agreements in place, which presents risks related to pricing, availability, quality, and delivery schedules. Interruptions or performance issues with these suppliers could significantly impact production and delay development, commercialization, clinical trials, and regulatory approvals. The company may encounter difficulties in securing alternative suppliers on reasonable terms and timelines, potentially affecting its business operations.
Sources:
Co diagnostics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Co diagnostics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
